Tag: FDA

23andMe Presents at FDA Advisory Panel Meeting on Direct-to-Consumer Genetic Tests

Editor's note: This post has been altered from the original. The slides from the presentation have been removed. 23andMe, like many others, believes that individuals have a right to access their own genetic information and that personal genetics will pave the way for significant advances in healthcare. ...

Read more

23andMe at FDA/CDRH Public Meeting on Oversight of Laboratory Developed Tests (LDTs)

The FDA/CDRH Public Meeting on Oversight of Laboratory Developed Tests (LDTs) took place yesterday and today (July 19 and 20) in Washington, DC. Webcasts of both days will be available from the FDA for the next year. 23andMe's President and Co-Founder Anne Wojcicki spoke about the promise and power of ...

Read more

Update on 23andMe and the FDA

On June 10, 2010, 23andMe received a letter from the Food and Drug administration (FDA) expressing the agency's view that our Personal Genome Service™ may be subject to FDA regulation.  We have responded to this letter and are in the process of scheduling a meeting with the agency for further discussions.  ...

Read more

FDA Adds Boxed Warning to Plavix Label to Highlight Reduced Effectiveness of the Drug In Poor Metabolizers

The U.S. Food and Drug Administration (FDA) has updated the label information for the commonly used anti-clotting medication Plavix® (clopidogrel) to stress to physicians that patients carrying certain genetic variations may not receive the full benefit from the drug. Plavix reduces the chance a harmful ...

Read more

FDA Updates Label for Commonly Used Blood Thinner to Include Dosing Recommendations Based on Genetics

Warfarin (Coumadin®) is a blood thinner given to people at high risk for the formation of blood clots due to conditions such as deep vein thrombosis, heart valve disease or replacement, and irregular heart beat. The drug is also given to prevent recurrence of pulmonary embolism, heart attack and stroke. If ...

Read more

Return to top